Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Supernus Pharmaceuticals, Inc. on June 12, 2018. As of April 13, 2018, there were 51,774,326 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on four proposals. All proposals were approved by the majority of votes cast. The tabulation of votes was as follows:
- Proposal 1 (Election of Class III Directors):
- Georges Gemayel, Ph.D.: 39,359,588 votes For; 3,856,013 votes Withheld.
- John M. Siebert, Ph.D.: 41,216,444 votes For; 1,999,157 votes Withheld.
- Proposal 2 (Ratification of KPMG LLP): 47,619,182 votes For; 107,060 votes Against; 24,928 Abstain.
- Proposal 3 (Executive Compensation - Say on Pay): 42,191,039 votes For; 918,823 votes Against; 105,739 Abstain.
- Proposal 4 (Amendment to 2012 Equity Incentive Plan): 41,209,799 votes For; 1,980,644 votes Against; 25,158 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the definitive proxy statement filed on April 27, 2018, for detailed background on the director nominees and equity plan amendments.
- Confirm the total number of shares outstanding (51,774,326) against the most recent 10-Q or 10-K filings to account for any post-April 13 changes.
- Note that approximately 4.5 million shares were subject to broker non-votes on Proposals 1, 3, and 4, indicating these shares were held in street name without specific instructions from beneficial owners.